Literature DB >> 31064292

Systemic Inhibition of Soluble Tumor Necrosis Factor with XPro1595 Exacerbates a Post-Spinal Cord Injury Depressive Phenotype in Female Rats.

Kaitlin Farrell1, John D Houle1.   

Abstract

Spinal cord injury (SCI) is associated with a three-fold risk of major depressive disorder compared with the general population. Current antidepressant therapy is often not as effective in this patient population, suggesting the need for a more efficacious therapeutic target. The goal of this study was to elucidate the role of inflammatory cytokine tumor necrosis factor (TNF) in the dorsal raphe nucleus (DRN, the principle source of serotonin to the brain) in the development and possible treatment of depression after SCI. A depressive phenotype following moderate T9 contusion was identified in adult female rats using a battery of behavioral tests (forced swim test, sucrose preference test, novel object recognition test, open field locomotion, and social exploration). Data revealed two clusters of injured rats (58%) that exhibit increased immobility in the forced swim test, indicating depressive phenotype or a melancholic-depressive phenotype with concomitant decrease in sucrose preference. ElevatedTNF levels in the DRN of these two clusters correlated with increased immobility in the forced swim test. We then tested the efficacy of soluble TNF inhibition with XPro1595 treatment to prevent the depressive phenotype after SCI. Subcutaneous (s.c.) delivery of XPro1595 caused an exacerbation of depressive phenotype, with all treated clusters exhibiting increased forced swim immobility compared with saline-treated non-depressed rats. Intracerebroventricular (i.c.v.) administration of the drug did not prevent or enhance the development of depression after injury. These results suggest a complex role for TNF-based neuroinflammation in SCI-induced depression that needs to be further explored, perhaps in conjunction with a broader targeting of additional post-SCI inflammatory cytokines.

Entities:  

Keywords:  TNF; depression; neuroinflammation; spinal cord injury

Mesh:

Substances:

Year:  2019        PMID: 31064292      PMCID: PMC6791477          DOI: 10.1089/neu.2019.6438

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  68 in total

1.  Remote activation of microglia and pro-inflammatory cytokines predict the onset and severity of below-level neuropathic pain after spinal cord injury in rats.

Authors:  Megan Ryan Detloff; Lesley C Fisher; Violetta McGaughy; Erin E Longbrake; Phillip G Popovich; D Michele Basso
Journal:  Exp Neurol       Date:  2008-04-20       Impact factor: 5.330

Review 2.  The forced swimming test as a model for core and component behavioral effects of antidepressant drugs.

Authors:  I Lucki
Journal:  Behav Pharmacol       Date:  1997-11       Impact factor: 2.293

3.  Inflammation is increased with anxiety- and depression-like signs in a rat model of spinal cord injury.

Authors:  Sioui Maldonado-Bouchard; Kelsey Peters; Sarah A Woller; Behrouz Madahian; Usef Faghihi; Shivani Patel; Shameena Bake; Michelle A Hook
Journal:  Brain Behav Immun       Date:  2015-08-18       Impact factor: 7.217

4.  TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting.

Authors:  Birgitte B Simen; Catharine H Duman; Arthur A Simen; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2006-02-03       Impact factor: 13.382

5.  Symptoms of major depression in people with spinal cord injury: implications for screening.

Authors:  Charles H Bombardier; J Scott Richards; James S Krause; David Tulsky; Denise G Tate
Journal:  Arch Phys Med Rehabil       Date:  2004-11       Impact factor: 3.966

6.  Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury.

Authors:  David P Stirling; Kourosh Khodarahmi; Jie Liu; Lowell T McPhail; Christopher B McBride; John D Steeves; Matt S Ramer; Wolfram Tetzlaff
Journal:  J Neurosci       Date:  2004-03-03       Impact factor: 6.167

7.  Soluble TNFα Signaling within the Spinal Cord Contributes to the Development of Autonomic Dysreflexia and Ensuing Vascular and Immune Dysfunction after Spinal Cord Injury.

Authors:  Eugene Mironets; Patrick Osei-Owusu; Valerie Bracchi-Ricard; Roman Fischer; Elizabeth A Owens; Jerome Ricard; Di Wu; Tatiana Saltos; Eileen Collyer; Shaoping Hou; John R Bethea; Veronica J Tom
Journal:  J Neurosci       Date:  2018-04-02       Impact factor: 6.167

8.  A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.

Authors:  Charles L Raison; Robin E Rutherford; Bobbi J Woolwine; Chen Shuo; Pamela Schettler; Daniel F Drake; Ebrahim Haroon; Andrew H Miller
Journal:  JAMA Psychiatry       Date:  2013-01       Impact factor: 21.596

9.  Prevalence of depression after spinal cord injury: a meta-analysis.

Authors:  Ryan Williams; Adrian Murray
Journal:  Arch Phys Med Rehabil       Date:  2014-09-16       Impact factor: 3.966

Review 10.  TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease.

Authors:  Melissa K McCoy; Malú G Tansey
Journal:  J Neuroinflammation       Date:  2008-10-17       Impact factor: 8.322

View more
  3 in total

Review 1.  The Role of Tumor Necrosis Factor Following Spinal Cord Injury: A Systematic Review.

Authors:  Minna Christiansen Lund; Bettina Hjelm Clausen; Roberta Brambilla; Kate Lykke Lambertsen
Journal:  Cell Mol Neurobiol       Date:  2022-05-23       Impact factor: 5.046

2.  Osteopenia in a Mouse Model of Spinal Cord Injury: Effects of Age, Sex and Motor Function.

Authors:  Michelle A Hook; Alyssa Falck; Ravali Dundumulla; Mabel Terminel; Rachel Cunningham; Arthur Sefiani; Kayla Callaway; Dana Gaddy; Cédric G Geoffroy
Journal:  Biology (Basel)       Date:  2022-01-26

Review 3.  Selective Targeting of TNF Receptors as a Novel Therapeutic Approach.

Authors:  Roman Fischer; Roland E Kontermann; Klaus Pfizenmaier
Journal:  Front Cell Dev Biol       Date:  2020-05-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.